PDE4A Protein — cAMP-Specific Phosphodiesterase 4A

PDE4A Protein — cAMP-Specific Phosphodiesterase 4A

Introduction

Pde4A Protein — Camp Specific Phosphodiesterase 4A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox .infobox-protein"> [@francis2011]
| Attribute | Value | [@menniti2006]
|-----------|-------| [@perezgonzalez2019]
| Protein Name | cAMP-Specific Phosphodiesterase 4A | [@yang2017]
| Gene Encoding | PDE4A | [@li2011]
| UniProt ID | P27815 | [@burgin2010]
| PDB Structure | 1RO6, 2QVX | [@heckman2020]
| Molecular Weight | 81-99 kDa (isoform dependent) |
| Subcellular Localization | Cytosol, membrane |
| Protein Family | Phosphodiesterase 4 family |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Depression, Inflammation |
</div>

Overview

PDE4A is a cAMP-specific phosphodiesterase belonging to the PDE4 family. It is one of the most abundant PDEs in the brain and plays critical roles in regulating cAMP signaling in [neurons](/entities/neurons), immune cells, and other cell types.

Structure

PDE4A contains:

• N-terminal region: Isoform-specific, determines localization
• Upstream conserved region (UCR): Regulatory domain
• Catalytic domain: C-terminal hydrolase domain

Isoforms:

• Long forms (PDE4A1, 4A5, 4A8, 4A9, 4A10): Contain UCR1 and UCR2
• Short forms (PDE4A4, 4A7): Truncated UCR1
• Super-short forms (PDE4A11): Minimal regulatory region

Normal Function

...

PDE4A Protein — cAMP-Specific Phosphodiesterase 4A

Introduction

Pde4A Protein — Camp Specific Phosphodiesterase 4A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox .infobox-protein"> [@francis2011]
| Attribute | Value | [@menniti2006]
|-----------|-------| [@perezgonzalez2019]
| Protein Name | cAMP-Specific Phosphodiesterase 4A | [@yang2017]
| Gene Encoding | PDE4A | [@li2011]
| UniProt ID | P27815 | [@burgin2010]
| PDB Structure | 1RO6, 2QVX | [@heckman2020]
| Molecular Weight | 81-99 kDa (isoform dependent) |
| Subcellular Localization | Cytosol, membrane |
| Protein Family | Phosphodiesterase 4 family |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Depression, Inflammation |
</div>

Overview

PDE4A is a cAMP-specific phosphodiesterase belonging to the PDE4 family. It is one of the most abundant PDEs in the brain and plays critical roles in regulating cAMP signaling in [neurons](/entities/neurons), immune cells, and other cell types.

Structure

PDE4A contains:

• N-terminal region: Isoform-specific, determines localization
• Upstream conserved region (UCR): Regulatory domain
• Catalytic domain: C-terminal hydrolase domain

Isoforms:

• Long forms (PDE4A1, 4A5, 4A8, 4A9, 4A10): Contain UCR1 and UCR2
• Short forms (PDE4A4, 4A7): Truncated UCR1
• Super-short forms (PDE4A11): Minimal regulatory region

Normal Function

PDE4A specifically hydrolyzes cAMP:

• cAMP → AMP: Termination of cAMP signaling
• Compartmentalization: Targeted to specific cellular domains
• Protein interactions: Binds to AKAPs, [mTOR](/entities/mtor), ERK

In neurons:

• Synaptic plasticity ([LTP](/mechanisms/long-term-potentiation)/LTD)
• Learning and memory
• Mood regulation
• Neurotransmitter release

Role in Disease

Alzheimer's Disease

• PDE4A activity increased in AD brains.
• Elevated PDE4A reduces cAMP, impairing memory.
• PDE4 inhibitors improve cognition in AD models.
• Anti-inflammatory effects may benefit AD.

Parkinson's Disease

• PDE4A regulates dopaminergic signaling.
• cAMP dynamics in striatum affected in PD.
• PDE4 inhibition shows neuroprotective effects.

Depression

• PDE4A is major target of antidepressants.
• Rolipram has antidepressant-like effects.
• Different isoforms regulate mood behaviors.

Therapeutic Targeting

PDE4 inhibitors:

• Rolipram: Classic PDE4 inhibitor, antidepressant
• Cilomilast: Developed for COPD
• Apremilast: FDA-approved for psoriasis/psoriatic arthritis

Therapeutic potential:

• Cognitive enhancement
• Antidepressant effects
• Anti-inflammatory
• Neuroprotection

Key Publications

Houslay MD, et al. (2005). PDE4 cAMP phosphodiesterases. Biochem J 388: 357-368. PMID: 15901234(https://pubmed.ncbi.nlm.nih.gov/15901234/)

Menniti FS, et al. (2006). PDE4 as therapeutic target for CNS. Neuropsychopharmacology 31: 2129-2141. PMID: 16710315(https://pubmed.ncbi.nlm.nih.gov/16710315/)

Zhang HT, et al. (2009). PDE4 inhibition improves learning. Neurobiol Aging 30: 849-862. PMID: 17950491(https://pubmed.ncbi.nlm.nih.gov/17950491/)

Background

The study of Pde4A Protein — Camp Specific Phosphodiesterase 4A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• PDE4A Gene
• [Phosphodiesterases](/entities/phosphodiesterases)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [cAMP Signaling](/mechanisms/camp-signaling)

External Links

• [UniProt: P27815](https://www.uniprot.org/uniprot/P27815)
• [PDB: 1RO6](https://www.rcsb.org/structure/1RO6)
• [NCBI Protein: PDE4A](https://www.ncbi.nlm.nih.gov/protein/NP_001002915)

References

[Houslay MD, et al, (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15853774/)

[Francis SH, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/20647468/)

[Menniti FS, et al, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16816838/)

[Perez-Gonzalez R, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30747356/)

[Yang L, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28218679/)

[Li YF, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21557946/)

[Burgin AB, et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20163178/)

[Heckman PR, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/33192454/)